AMO GRONINGEN BV

Their core work

AMO Groningen BV is a Dutch ophthalmic optics SME based in Groningen, working at the intersection of vision science and medical device development. Their core expertise covers the optical and biomechanical properties of the human eye — including aberrations, refractive error, accommodation, and structural conditions such as myopia and keratoconus — with a clear applied orientation toward intraocular lens design and clinical translation. In EU research consortia they function as an industry-side specialist, bridging the gap between academic eye modelling and commercially relevant vision correction products. Their participation in MSCA doctoral training networks also means they contribute to shaping the next generation of ophthalmic researchers at the science-industry boundary.

What they specialise in

How they've shifted over time

AMO Groningen entered EU research through EGRET-Plus (2016-2019), a glaucoma-focused doctoral training programme — their early engagement was narrow, tied to a specific disease and a training network role with no recorded technical keywords. By 2021, with OBERON, their scope had broadened substantially into the full opto-biomechanical landscape: physiological optics, eye modelling, aberrations, accommodation, myopia, keratoconus, and intraocular lenses all appear in a single project. The shift points toward a widening from disease-specific clinical research toward a deeper, product-oriented portfolio in refractive correction and lens technology.

AMO Groningen is moving deeper into the scientific foundations of ocular optics and biomechanics, positioning themselves as a research-connected industrial partner for projects developing next-generation intraocular lenses, myopia management devices, or computational eye models for surgical planning.

How they like to work

AMO Groningen has not led any EU project, consistently joining as a partner or third party within MSCA-ITN networks — structures built around training PhD students across academic-industry boundaries — which means they contribute specialist industrial knowledge while academic partners drive the research agenda. Their 21 unique partners across 11 countries from just two projects reflects the inherently large nature of MSCA-ITN consortia rather than an exceptionally broad personal network, though it does confirm their comfort operating in complex, multi-country collaborations. For a future partner, they are likely to be a reliable, expert-level contributor rather than a project driver.

Despite only two H2020 projects, AMO Groningen has connected with 21 unique partners across 11 countries, reflecting the large consortium structures typical of MSCA-ITN training networks in ophthalmology. Their network is primarily European, concentrated in academic and clinical institutions focused on vision science.

What sets them apart

As a Dutch SME embedded in MSCA ophthalmic research networks, AMO Groningen occupies an uncommon position at the boundary between academic vision science and commercial lens technology — a combination that most pure academic or pure industrial partners cannot offer. Their keyword profile across OBERON spans almost the full spectrum of refractive correction research, from corneal aberrations and biomechanics through to intraocular lens design, making them a credible and versatile industrial voice in EU health or medical device consortia. Consortia building projects around presbyopia treatment, myopia control, or AI-assisted ocular diagnostics would find in them an industry partner with existing EU network ties and demonstrated research engagement.

Highlights from their portfolio

• OBERON
  Their primary funded project (EUR 265,620) and the source of virtually all recorded technical keywords — spanning ocular optics, biomechanics, and intraocular lenses — making it the clearest evidence of AMO's full scientific and commercial scope.
• EGRET-Plus
  Their first EU engagement, in a prestigious European glaucoma doctoral training programme, establishing early credibility within the broader ophthalmic research community before their deeper optical focus emerged.